Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Pancreatic Neoplasms 1Malignant Solid Neoplasm 1Lung Neoplasms 1Duodenal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Iopamidol × Clear all
NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Stanford University

Phase 1 Terminated
4 enrolled 11 charts
Breast

Breast Neoplasms

NCT02380209 2016-10-27

An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer

University of Arizona

Phase EARLY_PHASE1 Terminated
8 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡